Clinical Trial Update: A Study of Longer Interval of IVT IBI302 in Subjects With nAMD [Phase 2]

View source ↗

Summary

Phase 2 study evaluating a longer interval between IVT IBI302 injections in neovascular age-related macular degeneration; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• IVT IBI302 (IBI-302)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED